Tempest Therapeutics
Open
$2.02
Prev. Close
$2.02
High
$2.02
Low
$1.99
Market Snapshot
$7.73M
-0.3
-19.46
4
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
emptyResult
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Recently from Cashu
Tempest Therapeutics Unveils TP-145: A Promising New Drug in Immuno-Oncology
Tempest Therapeutics Advances in Immuno-Oncology with New Drug Candidate Tempest Therapeutics, a leading player in the field of immuno-oncology, announces a significant development in its pipeline wit…
Tempest Therapeutics: Key Insights and Developments in Recent Stock Performance and Future Outlook
Please provide the content you would like me to summarize, and I will create an article for you.
Tempest Therapeutics Expands Oncology Portfolio with Acquisition of Dual-CAR T Programs
Tempest Therapeutics Expands CAR T-Cell Therapy Portfolio Through Strategic Acquisition Tempest Therapeutics Inc. has recently announced a pivotal acquisition that could reshape its strategic directio…
Tempest Therapeutics Acquires Dual-CAR T Programs to Strengthen Oncology Portfolio
Tempest Therapeutics Expands CAR T-Cell Therapy Portfolio with Strategic Acquisition Tempest Therapeutics Inc. strengthens its position in the oncology market by announcing an all-stock acquisition of…